Zygomycosis: Conventional laboratory diagnosis

Clinical Microbiology and Infection

Volumn 15, Issue SUPPL. 5, 2009, Pages 60-65

  Lass Florl C ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Diagnosis; Mucorales; Zygomycetes; Zygomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGAL REPRODUCTION; FUNGUS CULTURE; FUNGUS HYPHAE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HISTOPATHOLOGY; HUMAN; INFECTION PREVENTION; LABORATORY DIAGNOSIS; LUNG BIOPSY; MINIMUM INHIBITORY CONCENTRATION; MUCORALES; MUCORMYCOSIS; OPPORTUNISTIC INFECTION; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; REVIEW; SPECIES IDENTIFICATION; SPORANGIOSPORE; TISSUE NECROSIS;

FUNGI; MUCORALES; ZYGOMYCETES;

CULTURE MEDIA; HISTOCYTOCHEMISTRY; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MUCORALES; MUCORMYCOSIS; STAINING AND LABELING;

EID: 70349977638     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02999.x     Document Type: Review

References (33)

1. Almyroudis N, Sutton D, Linden P, Rinaldi M, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant centre and review of the literature. Am J Transplant 2006, 6:2365-2375.
2. Upton A, Marr AK. Emergence of opportunistic mould infections in the haematopoietic stem cell transplant patient. Curr Infect Dis Rep 2006, 8:434-441.
3. Walsh T, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004, 10:48-66.
4. Chayakulkeeree M, Ghannoum M, Perfect J. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006, 25:215-229.
5. Rippon J. Zygomycosis. Mycopathologia 1988, 3:681-713.
6. Branscomb R. An overview of Mucormycosis. Lab Med 2002, 23:453-455.
7. Fridkin S. The changing face of fungal infections in health care settings. Clin Infect Dis 2005, 41:1455-1460.
8. Kauffman C, Malani A. Zygomycosis: an emerging fungal infection with new options for management. Curr Infect Dis Rep 2008, 9:435-440.
9. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer centre. Clin Infect Dis 2000, 30:851-856.
10. Lass-Flörl C, Resch G, Nachbaur D. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007, 45:101-104.
11. Pagano L, Offidani M, Fianchi L. Mucormycosis in haematologic patients. Haematologica 2004, 89:207-214.
12. Patterson T. Advances and challenges in management of invasive mycoses. Lancet 2005, 17:1013-1025.
13. Richardson C, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008, 14(suppl 4):5-24.
14. Kontoyiannis D, Lionakis M, Lewis R. Zygomycosis in a tertiary care cancer centre in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
15. Rickerts V, Just-Nübling G, Konrad F. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. Eur J Clin Microbiol Infect Dis 2006, 25:8-13.
16. Roychowdhury M, Pambuccian S, Aslan D. Pulmonary complications after bone marrow transplantation: an autopsy study from a large transplantation centre. Arch Pathol Lab Med 2005, 129:366-371.
17. Trifilio SM, Bennett CL, Yarnold PR. Breakthrough zygomycosis after voriconazole administration among patients with haematologic malignancies who receive haematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007, 39:425-429.
18. Vigouroux S, Morin O, Moreau P. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with haematologic disease: attention required. Clin Infect Dis 2005, 40:35-37.
19. Chamilos G, Marom E, Lewis R, Lionakis M, Kontoyiannis D. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005, 41:60-66.
20. Chamilos G, Luna M, Lewis R. Invasive fungal infections in patients with haematologic malignancies in a tertiary care cancer centre: an autopsy study over a 15-year period (1989-2003). Haematologica 2006, 91:986-989.
21. Glazer M, Nusair S, Breuer R, Lafair J, Sherman Y, Berkman N. The role of BAL in the diagnosis of pulmonary Mucormycosis. Chest 2000, 117:279-282.
22. Chakrabarti A, Das A, Sharma A. Ten years' experience in zygomycosis at a tertiary care centre in India. J Infect 2001, 42:261-266.
23. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007, 45:321-346.
24. Torres-Narbona M, Guinea J, Martinez-Alarcon J, Munoz P, Pelaez T, Emilio B. Workload and clinical significance of the isolation of Zygomycetes in a tertiary general hospital. Med Mycol 2008, 46:225-231.
25. Torres-Narbona M, Guinea J, Martínez-Alarcón J, Munoz P, Gadea I, Bouza E. Impact of zygomycosis on microbiology workload: a survey study in Spain. J Clin Microbiol 2007, 45:2051-2053.
26. Ribes J, Vanover-Sams C, Baker D. Zygomycetes in human disease. Clin Microbiol Rev 2000, 13:236-301.
27. Wysong D, Waldorf AR. Electrophoretic and immunoblot analyses of Rhizopus arrhizus antigens. J Clin Microbiol 1987, 25:358-363.
28. Suita Y, Satoh S, Miyagawa Y. A suspected case of orbital mucormycosis. Nippon Ganka Gakki Zasshi 2007, 111:16-21.
29. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 14:982-984.
30. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. M38-A 2002, Wayne, PA, Clinical Laboratory Standard Institute
31. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008, 52:1396-1400.
32. Lass-Flörl C, Mayr A, Perkhofer S. The activities of antifungal agents against yeasts and filamentous fungi: assessment according to EUCAST methodology. Antimicrob Agents Chemother 2008, 52:3637-3641.
33. Perkhofer S, Locher M, Cuenca-Estrella M. Posaconazole enhances the activity of amphotericin B against hyphae of Zygomycetes in vitro. Antimicrob Agents Chemother 2008, 52:2636-2638.